MediciNova, Inc., a biopharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code Number: 4875), today announced the initiation of its Phase III clinical program to determine the safety and efficacy of its novel oral treatment for bronchial asthma (MN-001) in asthma patients. The first Phase III trial in this program will involve approximately 705 asthma patients enrolled at 75 - 90 clinical sites in the U.S. [click link for full article]
(more...)